FF 10501

Drug Profile

FF 10501

Alternative Names: FF 10501 01; FF-10501

Latest Information Update: 30 May 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator FUJIFILM Holdings Corporation
  • Developer FUJIFILM Holdings Corporation; Strategia Therapeutics
  • Class Antineoplastics
  • Mechanism of Action Cell differentiation stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase I/II Acute myeloid leukaemia; Chronic myelomonocytic leukaemia; Myelodysplastic syndromes

Most Recent Events

  • 03 Apr 2018 Fujifilm Pharmaceuticals plans a phase II trial for Myelodysplastic syndrome (Combination therapy) (PO, Tablet) (NCT03486353)
  • 30 May 2017 FF 10501 is still in phase I trials for Myelodysplastic-syndromes in Japan (PO, Tablet)
  • 28 Apr 2017 Fujifilm completes a phase I trial in Myelodysplastic syndromes in Japan (PO) (JapicCTI132093)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top